Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, including viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood System for platelets and plasma is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells that inactivates blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, the Commonwealth of Independent States, the Middle East, Latin America, Europe, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
News: CERS +11.8% (to receive up to $180 mln of funding over 5 years to advance its INTERCEPT red blood cell program)
